देश: कनाडा
भाषा: अंग्रेज़ी
स्रोत: Health Canada
DESVENLAFAXINE (DESVENLAFAXINE SUCCINATE)
TARO PHARMACEUTICALS INC
N06AX23
DESVENLAFAXINE
50MG
TABLET (EXTENDED-RELEASE)
DESVENLAFAXINE (DESVENLAFAXINE SUCCINATE) 50MG
ORAL
15G/50G
Prescription
Active ingredient group (AIG) number: 0152509001; AHFS:
APPROVED
2022-10-20
PRODUCT MONOGRAPH PR TARO-DESVENLAFAXINE desvenlafaxine extended-release tablets 50 mg and 100 mg desvenlafaxine (as desvenlafaxine succinate monohydrate ) Antidepressant Taro Pharmaceuticals Inc. Date of Revision: 130 East Drive OCT 19, 2022 Brampton, Ontario L6T 1C1 Submission Control No.: 264187 _________________________________________________________________________________________ _Taro-Desvenlafaxine (desvenlafaxine succinate monohydrate) Product Monograph _ _Page 2 of 52_ TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFOR M ATION ............................................................................. 3 SUMMARY PRODUCT INFORMATION ................................................................................................... 3 INDICATIONS AND CLINICAL USE ......................................................................................................... 3 CONTRAINDICATIONS .............................................................................................................................. 4 WARNINGS AND PRECAUTIONS ............................................................................................................ 4 ADVERSE REACTIONS ............................................................................................................................11 DRUG INTERACTIONS .............................................................................................................................21 DOSAGE AND ADMINISTRATION .........................................................................................................24 OVERDOSAGE ...........................................................................................................................................27 ACTION AND CLINICAL PHARMACOLOGY .......................................................................................28 STORAGE AND STABILITY ....................................................................................................................31 SPECIAL HANDLING INSTRUCTIONS . पूरा दस्तावेज़ पढ़ें